1. Home
  2. BBIO vs ALGN Comparison

BBIO vs ALGN Comparison

Compare BBIO & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • ALGN
  • Stock Information
  • Founded
  • BBIO 2015
  • ALGN 1997
  • Country
  • BBIO United States
  • ALGN United States
  • Employees
  • BBIO N/A
  • ALGN N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • ALGN Industrial Specialties
  • Sector
  • BBIO Health Care
  • ALGN Health Care
  • Exchange
  • BBIO Nasdaq
  • ALGN Nasdaq
  • Market Cap
  • BBIO 10.4B
  • ALGN 9.9B
  • IPO Year
  • BBIO 2019
  • ALGN N/A
  • Fundamental
  • Price
  • BBIO $61.73
  • ALGN $134.51
  • Analyst Decision
  • BBIO Strong Buy
  • ALGN Buy
  • Analyst Count
  • BBIO 18
  • ALGN 13
  • Target Price
  • BBIO $74.28
  • ALGN $190.50
  • AVG Volume (30 Days)
  • BBIO 2.7M
  • ALGN 1.3M
  • Earning Date
  • BBIO 10-29-2025
  • ALGN 10-29-2025
  • Dividend Yield
  • BBIO N/A
  • ALGN N/A
  • EPS Growth
  • BBIO N/A
  • ALGN N/A
  • EPS
  • BBIO N/A
  • ALGN 5.16
  • Revenue
  • BBIO $353,780,000.00
  • ALGN $3,982,622,000.00
  • Revenue This Year
  • BBIO $123.32
  • ALGN $2.48
  • Revenue Next Year
  • BBIO $73.46
  • ALGN $3.44
  • P/E Ratio
  • BBIO N/A
  • ALGN $26.12
  • Revenue Growth
  • BBIO 62.46
  • ALGN 0.56
  • 52 Week Low
  • BBIO $21.72
  • ALGN $122.00
  • 52 Week High
  • BBIO $69.48
  • ALGN $246.19
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 59.65
  • ALGN 49.86
  • Support Level
  • BBIO $60.23
  • ALGN $131.90
  • Resistance Level
  • BBIO $64.44
  • ALGN $138.50
  • Average True Range (ATR)
  • BBIO 3.05
  • ALGN 4.57
  • MACD
  • BBIO 0.06
  • ALGN 0.10
  • Stochastic Oscillator
  • BBIO 53.68
  • ALGN 17.76

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: